Form 8-K - Current report:
SEC Accession No. 0001144204-13-051455
Filing Date
2013-09-18
Accepted
2013-09-18 17:22:21
Documents
6
Period of Report
2013-09-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K v355360_8k.htm 8-K 24949
2 EXHIBIT 4.1 v355360_ex4-1.htm EX-4.1 668015
3 EXHIBIT 4.2 v355360_ex4-2.htm EX-4.2 56206
4 EXHIBIT 10.1 v355360_ex10-1.htm EX-10.1 281375
5 EXHIBIT 99.1 v355360_ex99-1.htm EX-99.1 12806
6 GRAPHIC tex99-1logo.jpg GRAPHIC 11357
  Complete submission text file 0001144204-13-051455.txt   1060727
Mailing Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100
Business Address 2 SNUNIT ST SCIENCE PARK, POB 455 CARMIEL L3 20100 972-4-988-9488
Protalix BioTherapeutics, Inc. (Filer) CIK: 0001006281 (see all company filings)

EIN.: 650643773 | State of Incorp.: FL | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33357 | Film No.: 131104174
SIC: 2836 Biological Products, (No Diagnostic Substances)